This Article Full Text Full Text (PDF) All Versions of this Article: 200411-1537OCv1 172/6/772    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yates, B. Articles by Corris, P. A. Search for Related Content PubMed PubMed Citation Articles by Yates, B. Articles by Corris, P. A.

Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome

William Leech Centre for Lung Research, The Freeman Hospital, High Heaton, Newcastle upon Tyne, United Kingdom

Correspondence and requests for reprints should be addressed to Paul A. Corris, The William Leech Centre for Lung Research, The Freeman Hospital, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. E-mail: Paul.Corris{at}ncl.ac.uk

Introduction: A recent pilot study noted clinical benefit of macrolide therapy in the management of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition previously regarded as irreversible. Objective: To examine the effect of low-dose macrolides on lung function in lung allograft recipients with established BOS and to assess whether this benefit is sustained. Methods: We retrospectively evaluated the effect of azithromycin (250 mg alternate days) on clinical status and lung function in 20 allograft recipients with established BOS, confirmed by decline in FEV₁ or FEF_25–75; consistent high-resolution computed tomography findings; and exclusion of acute rejection, infection, or anastomatic complications. Azithromycin was introduced at mean 82 months after transplantation. BOS staging at initiation of treatment was BOS 3 (10), BOS 2 (2), BOS 1 (6), and BOS0-p (2). All patients were on maintenance immunosuppression comprising cell-cycle inhibitor, oral corticosteroids, and calcineurin inhibitor. Results: There was a significant increase in FEV₁ of median 110 ml (range, –70 to 730 ml) between baseline and 3 months of azithromycin therapy (p = 0.002). This improvement was sustained beyond 3 months in the majority of patients, who had initially benefited from azithromycin (up to 11 months follow up). Conclusions: This case series confirms the benefit of azithromycin in not only halting, but reversing the declining lung function seen in patients with BOS. This benefit appears to be maintained over time. Low-dose macrolides offer a new and exciting therapeutic strategy for the treatment of progressive BOS, and further clinical and translational mechanistic studies are required.

Key Words: lung • macrolide • transplantation

This article has been cited by other articles:

				R. Stamatiou, E. Paraskeva, K. Boukas, K. I. Gourgoulianis, P-A. Molyvdas, and A. A. Hatziefthimiou Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells Eur. Respir. J., September 1, 2009; 34(3): 721 - 730. [Abstract] [Full Text] [PDF]

				K. M. Williams, J. W. Chien, M. T. Gladwin, and S. Z. Pavletic Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation JAMA, July 15, 2009; 302(3): 306 - 314. [Abstract] [Full Text] [PDF]

				J. A. Belperio, S. S. Weigt, M. C. Fishbein, and J. P. Lynch III Chronic Lung Allograft Rejection: Mechanisms and Therapy Proceedings of the ATS, January 15, 2009; 6(1): 108 - 121. [Abstract] [Full Text] [PDF]

				P. A. J. Crosbie and M. A. Woodhead Long-term macrolide therapy in chronic inflammatory airway diseases Eur. Respir. J., January 1, 2009; 33(1): 171 - 181. [Abstract] [Full Text] [PDF]

				S. M. Levine Lung Transplantation ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 563 - 584. [Full Text] [PDF]

				B. M. Vanaudenaerde, I. Meyts, R. Vos, N. Geudens, W. De Wever, E. K. Verbeken, D. E. Van Raemdonck, L. J. Dupont, and G. M. Verleden A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy Eur. Respir. J., October 1, 2008; 32(4): 832 - 842. [Abstract] [Full Text] [PDF]

				J. Gottlieb Review: Update on lung transplantation Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 237 - 247. [Abstract] [PDF]

				A. Knyazhitskiy, R. G. Masson, R. Corkey, and J. Joiner Beneficial Response to Macrolide Antibiotic in a Patient With Desquamative Interstitial Pneumonia Refractory to Corticosteroid Therapy Chest, July 1, 2008; 134(1): 185 - 187. [Abstract] [Full Text] [PDF]

				M.-K. Song, A. De Vito Dabbs, S. M. Studer, and S. E. Zangle Course of Illness after the Onset of Chronic Rejection in Lung Transplant Recipients Am. J. Crit. Care., May 1, 2008; 17(3): 246 - 253. [Abstract] [Full Text] [PDF]

				E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]

				D. M Murphy, I. A Forrest, C. Ward, P. A Corris, G. E Johnson, D. Jones, A. J Fisher, J. J Egan, T. E Cawston, and J. L Lordan Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts Thorax, September 1, 2007; 62(9): 834 - 834. [Full Text] [PDF]

				J.-F. Cordier Challenges in pulmonary fibrosis {middle dot} 2 : Bronchiolocentric fibrosis Thorax, July 1, 2007; 62(7): 638 - 649. [Abstract] [Full Text] [PDF]

				R. Stovold, I. A. Forrest, P. A. Corris, D. M. Murphy, J. A. Smith, S. Decalmer, G. E. Johnson, J. H. Dark, J. P. Pearson, and C. Ward Pepsin, a Biomarker of Gastric Aspiration in Lung Allografts: A Putative Association with Rejection Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1298 - 1303. [Abstract] [Full Text] [PDF]

				A. Van Muylem, C. Knoop, and M. Estenne Early Detection of Chronic Pulmonary Allograft Dysfunction by Exhaled Biomarkers Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 731 - 736. [Abstract] [Full Text] [PDF]

				P. A. Corris and J. D. Christie Update in Transplantation 2006 Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 432 - 435. [Full Text] [PDF]

				J. F. McDyer Human and Murine Obliterative Bronchiolitis in Transplant Proceedings of the ATS, January 1, 2007; 4(1): 37 - 43. [Abstract] [Full Text] [PDF]

				T. K. Trow Clinical Year in Review I: Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology Proceedings of the ATS, September 1, 2006; 3(7): 553 - 556. [Full Text] [PDF]

				G. M. Verleden, B. M. Vanaudenaerde, L. J. Dupont, and D. E. Van Raemdonck Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Bronchiolitis Obliterans Syndrome Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 566 - 570. [Abstract] [Full Text] [PDF]

				L. P. Nicod Mechanisms of airway obliteration after lung transplantation. Proceedings of the ATS, July 1, 2006; 3(5): 444 - 449. [Abstract] [Full Text] [PDF]

				M. Estenne and R. M. Kotloff Update in transplantation 2005. Am. J. Respir. Crit. Care Med., March 15, 2006; 173(6): 593 - 598. [Full Text] [PDF]

				L. F. Angel, D. Levine, J. Sanchez, and S. Levine Azithromycin in Bronchiolitis Obliterans: Is the Evidence Strong Enough? Am. J. Respir. Crit. Care Med., February 15, 2006; 173(4): 465 - 466. [Full Text] [PDF]

				J. B. Orens, J. F. McDyer, and R. E. Girgis Azithromycin in Bronchiolitis Obliterans: Is the Evidence Strong Enough? Am. J. Respir. Crit. Care Med., February 15, 2006; 173(4): 466 - 466. [Full Text] [PDF]

				T. J. Williams and G. M. Verleden Azithromycin: A Plea for Multicenter Randomized Studies in Lung Transplantation Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 657 - 659. [Full Text] [PDF]